文献速递心力衰竭与心肌病

预防性ACEI与杜氏肌营养不良总生存期的关联:注册数据分析

Association between prophylactic angiotensin-converting enzyme inhibitors and overall survival in Duchenne muscular dystrophy-analysis of registry data.
PubMed 文献 · Eur Heart J · 2021-01-01

基于法国多中心DMD心脏注册研究,纳入576例8-13岁左室功能正常的DMD患者,采用Cox时依模型和倾向性分析评估预防性ACEI与生存的关联。结果显示预防性ACEI与更低的全因死亡风险及心衰住院风险相关,敏感性分析结果一致。

要点

  • 预防性ACEI治疗与DMD患者全因死亡风险降低相关(HR 0.49)。
  • 倾向性分析中ACEI与更低死亡风险(HR 0.39)和心衰住院风险(HR 0.16)相关。
  • 多项敏感性分析结果一致,支持预防性ACEI的生存获益。

核心结论

  • 在左室功能正常的DMD患者中,预防性ACEI治疗与显著更高的总生存率和更低的心衰住院率相关。

研究设计与样本

  • 分析法国多中心DMD心脏注册研究(NCT03443115)数据。
  • 纳入668例8-13岁左室功能正常的DMD患者,其中576例符合条件,390例接受预防性ACEI。
  • 采用Cox时依模型、倾向性评分分析和多项敏感性分析。

主要发现

  • 预防性ACEI组死亡53例(13.5%),未预防性ACEI组死亡60例(32.3%)。
  • Cox时依模型校正基线变量后,ACEI治疗与全因死亡风险降低相关(HR 0.49,95%CI 0.34-0.72)。
  • 倾向性分析中,治疗组和对照组12年估计死亡概率分别为18.5%和30.4%。
  • ACEI与更低死亡风险(HR 0.39,95%CI 0.17-0.92)和心衰住院风险(HR 0.16,95%CI 0.04-0.62)相关。
  • 所有其他敏感性分析结果一致。

临床怎么用

  • 对于左室功能正常的8-13岁DMD患者,可考虑预防性使用ACEI以改善生存并减少心衰住院。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To estimate the effect of prophylactic angiotensin-converting enzyme inhibitors (ACEi) on survival in Duchenne muscular dystrophy (DMD). METHODS AND RESULTS: We analysed the data from the French multicentre DMD Heart Registry (ClinicalTrials.gov: NCT03443115). We estimated the association between the prophylactic prescription of ACEi and event-free survival in 668 patients aged 8 to 13 years, with normal left ventricular function, using (i) a Cox model with intervention as a time-dependent covariate, (ii) a propensity-based analysis comparing ACEi treatment vs. no treatment, and (iii) a set of sensitivity analyses. The study outcomes were overall survival and hospitalizations for heart failure (HF) or acute respiratory failure. Among the 668 patients included in the DMD Heart Registry, 576 (mean age 6.1 ± 2.8 years) were eligible for this study, of whom 390 were treated with ACEi prophylactically. Death occurred in 53 patients (13.5%) who were and 60 patients (32.3%) who were not treated prophylactically with ACEi, respectively. In a Cox model with intervention as a time-dependent variable, the hazard ratio (HR) associated with ACEi treatment was 0.49 [95% confidence interval (CI) 0.34-0.72] and 0.47 (95% CI 0.31-0.17) for overall mortality after adjustment for baseline variables. In the propensity-based analysis, 278 patients were included in the treatment group and 834 in the control group, with 18.5% and 30.4% 12-year estimated probability of death, respectively. ACEi were associated with a lower risk of death (HR 0.39; 95% CI 0.17-0.92) and hospitalization for HF (HR 0.16; 95% CI 0.04-0.62). All other sensitivity analyses yielded similar results. CONCLUSION: Prophylactic ACEi treatment in DMD was associated with a significantly higher overall survival and lower rates of hospitalization for HF.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Porcher R, Desguerre I, Amthor H, et al. Association between prophylactic angiotensin-converting enzyme inhibitors and overall survival in Duchenne muscular dystrophy-analysis of registry data. Eur Heart J. 2021. PMID: 33748842. doi:10.1093/eurheartj/ehab054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。